Eli Lilly submits tirzepatide for approval in US and EU

Both the FDA and EMA have accepted Eli Lilly's marketing approval applications for its type 2 diabetes treatment, tirzepatide, the US-based pharmaceutical firm announces, also reporting that applications for seven additional markets have been submitted.

Photo: Mike Blake/Reuters/Ritzau Scanpix

Eli Lilly's tirzepatide, presumably the biggest contender for Novo Nordisk's newest generation of diabetes drugs, has taken a pivotal step on the pathway toward future market launches.

During an investment community meeting on Wednesday, Eli Lilly announced that it has submitted the type 2 diabetes drug for marketing approvals in the EU, US, Japan and an additional six other international markets.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs